Reduction of Atrial Fibrillation Study in Patients Undergoing Coronary Artery Bypass Grafting. (RASCABG 1 Study)

• Status: Completed
• Trial end date: 2005-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether postoperatively oral treatment with high dosis amiodarone for five days after intravenously admitted bolusinfusion will minimize the risk for development of atrial fibrillation after coronary artery bypass grafting.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Aarhus
• Treatments: Amiodarone

Criteria

Inclusion Criteria:

• enlistment for an elective CABG

• age more than 18 years

• willingness to be randomised

• provision of informed consent

Exclusion Criteria:

• enlistment for other types of heart surgery

• earlier heart surgery

• resting heart rate below 40 bpm.

• AV-blockage of any degree

• preoperative atrial fibrillation or flutter

• former known atrial fibrillation or flutter lasting more than one month

• hepatic dysfunction (ALAT > twice the upper normal limit)

• hyperthyroidism

• pregnancy

• breastfeeding

• known adverse reactions to amiodarone